NCT02493361View on ClinicalTrials.gov

Trial of pIL-12/MK-3475 in Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 17, 2015

Primary Completion Date

April 26, 2018

Study Completion Date

March 2, 2020

Conditions
Melanoma
Interventions
DRUG

Pembrolizumab

DRUG

pIL-12

Trial Locations (2)

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

94115

University of San Francisco, California, San Francisco

All Listed Sponsors
collaborator

OncoSec Medical Incorporated

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT02493361 - Trial of pIL-12/MK-3475 in Metastatic Melanoma | Biotech Hunter | Biotech Hunter